Pharmacoeconomic efficiency of the exhaled nitric oxide monitoring for the purpose of personalized basic therapy for children with atopic asthma
Year: 2014, volume 10 Issue: №1 Pages: 196-199
Heading: Parmacology Article type: Original article
Authors: Petrov V.I., Shishimorov I.N., Magnitskaya O.V., Ponomareva Ju.V.
Organization: Volgograd State Medical University
Heading: Parmacology Article type: Original article
Authors: Petrov V.I., Shishimorov I.N., Magnitskaya O.V., Ponomareva Ju.V.
Organization: Volgograd State Medical University
Summary:
effectiveness of basic therapy for atopic asthma in children. Material and Methods. A 24-week, prospective, comparative, randomized, open-label study in parallel groups was performed. There were included 70 children with uncontrolled atopic asthma with high FeNO (FeNO>50ppb). There were evaluated the comparative efficacy of selection of basic therapy by using monthly monitoring of FeNO and criteria of asthma control in accordance with the recommendations of GINA (2011). Results. The cost / effective ratio (CER) for achievement of one permanent 12 week-control after 24 weeks of therapy in group of monitoring FeNO was 11433,26 rubles, which was 40% lower, than the CER in the comparison group (18382,99 rubles). Conclusion. The using of FeNO monitoring for a personalized correction of basic therapy in children with uncontrolled atopic asthma can reduce the cost of treatment and is also economically viable.
Bibliography:
1. The national program "Children bronchial asthma: strategy of treatment and prevention". Moscow: Original-maket, 2008; 184 p. (Национальная программа «Бронхиальная астма у детей: стратегия лечения и профилактика». М: Оригинал-макет, 2008; 184 с.;
2. Thomas М, Gruffydd-Jones К, Stonham С, et al. Assessing asthma control in routine clinical practice: use of the Royal College of Physicians '3 questions'. Prim Care Respir J 2009; 18 (2): 83-8;
3. Malinovschi A, Fonseca JA, Jacinto T, et al. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013; 132 (4): 821-7.
4. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) 2011. www.ginaasthma.com;
5. Stanley J. Szefler, Herman Mitchell, Christine A. Sorkness, et al. Adding Exhaled Nitric Oxide to Guideline-based Asthma Treatment in Inner-City Adolescents and Young Adults: a randomized controlled trial. Lancet 2008; 372 (9643): 1065-1072;
6. George W. Rodway, JiYeon Choi, Leslie A. Hoffman, et al. Exhaled nitric oxide in the diagnosis and management of asthma: clinical implications. Chron Respir 2009; 6 (1): 19-29;
7. Taylor DR, Pijnenburg MW, Smith AD, et al. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006; 61 (9): 817-27;
8. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67 (3): 199-208;
9. Martha Scott, Abid Raza, Wilfried Karmaus, et al. Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study. Thorax 2010; 65 (3): 258-262;
10. Katayoun Bahadori, Mary M Doyle-Waters, Carlo Marra, et al. Economic burden of asthma: a systematic review. ВМС Pulm Med 2009; 9: 24;
11. Gorbunov VA, Magnitskaya OV, Ponomareva JuV, et al. Pharmacoeconomic justification forthe choice of initial therapy of uncontrolled bronchial asthma in young children.Journal of Volgograd State Medical University 2013: 4 (48): 110-112.
| Attachment | Size |
|---|---|
| 2014_01-01_196-199.pdf | 523.51 KB |
Русский
English